An evaluation of carrier agents for desferoxamine, an up-regulator of vascular endothelial growth factor

Avascularity and hypoxia result in avascular necrosis and play a negative role in fracture healing. The FDA-approved iron chelating agent, desferoxamine (DFO) in a liquid form, has been shown to induce angiogenesis and improve fracture healing through upregulation of the vascular endothelial growth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of biomaterials applications 2013-05, Vol.27 (8), p.1046-1054
Hauptverfasser:	Hertzberg, Brian P, Holt, Joshua B, Graff, Ronald D, Gilbert, Shawn R, Dahners, Laurence E
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biocompatible Materials - chemistry Bone Matrix - chemistry Bones Calcium Sulfate - chemistry Carriers Collagen - chemistry Controlled release Deferoxamine - administration & dosage Drug Carriers - chemistry Drug Delivery Systems Evaluation Female Fracture Healing - drug effects Fracture mechanics Growth factors Healing Humans Hypoxia-Inducible Factor 1 - metabolism Materials Testing Mice Mice, Inbred C57BL Neovascularization, Physiologic - drug effects Osteonecrosis - drug therapy Osteonecrosis - therapy Pellets Pregnancy Up-Regulation - drug effects Vascular Endothelial Growth Factor A - biosynthesis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!